COVID-19

[Windtree Therapeutics, Inc.] Windtree Therapeutics, Inc. announced results from its Phase II study of lucinactant for patients with severe COVID-19 associated ARDS and lung injury.

[Eye] Scientists investigated whether SARS-CoV-2 caused morphological changes in the corneal sub-basal nerve plexus of post-COVID-19 patients using in vivo confocal microscopy.

[Biotechnology and Bioengineering] Investigators reported the optimization of the production of VSV-ΔG-spike vaccine in Vero cells using the Ambr15 system.

[STAT News] One lesson is to only trust the most rigorous studies, known as randomized controlled clinical trials. But an equally important one: We need to get much better at conducting these rigorous studies more quickly and cheaply — and that goes beyond the COVID pandemic.

[eLife] The authors explore the potential pathogenic metabolic mechanisms that could underly both severe acute COVID-19 and post-acute sequelae of CoV-2, and then consider how these might be targeted for future therapeutic approaches.

[AIM ImmunoTech, Inc.] AIM ImmunoTech, Inc. announced it has received notification from the FDA that the FDA’s Clinical Hold on AIM’s investigational new drug (IND) application for a Phase II study of Ampligen as a therapy for locally advanced pancreatic cancer has been lifted and the company may proceed with the study.